Pluri Inc

4DX

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

ASX listed gold miner under pressure due to lower production

Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.
stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,850.0016.500.19%
CAC 407,974.4938.520.49%
DAX 4023,730.92166.910.71%
Dow JONES (US)46,993.2646.850.10%
FTSE 10010,403.6085.910.83%
HKSE25,827.9940.55-0.16%
NASDAQ22,479.53105.350.47%
Nikkei 22555,038.371,337.982.49%
NZX 50 Index13,281.1498.910.75%
S&P 5006,716.0916.710.25%
S&P/ASX 2008,645.2019.000.22%
SSE Composite Index4,033.6216.29-0.40%

Market Movers